comparemela.com
  1. Home
  2. Live Updates
  3. Trial Identifier - Breaking News

Latest Breaking News On - Trial identifier - Page 5 : comparemela.com

InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial

CGuard Carotid Stent will now be a treatment option in the stenting plus medical therapy arm of the trial for patients

United statesThomas brottMarvin slosmanInspiremd incDrug administrationEmbolic prevention stent systemCarotid stentCarotid revascularizationendarterectomyStenting trialInvestigational device exemptionChief executive officerPrincipal investigatorCarotid revascularizationMedical managementAsymptomatic carotid stenosis trialTrial identifier

Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

/PRNewswire/ Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative.

Victor perlrothExchange commissionPrnewswire kodiak sciences incKodiak sciencesPivotal programSecurities exchangeKodiak sciences incChief executive officerLonza kodiak ibex dedicateFull yearTerm performance incentive planAntibody biopolymer conjugateTrial identifierTrial identifiersPalo altoSecurities act

Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

/PRNewswire/ Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative.

Victor perlrothExchange commissionPrnewswire kodiak sciences incKodiak sciencesPivotal programSecurities exchangeKodiak sciences incChief executive officerLonza kodiak ibex dedicateFull yearTerm performance incentive planAntibody biopolymer conjugateTrial identifierTrial identifiersPalo altoSecurities act

Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/  Kodiak Sciences Inc. today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical. | February 23, 2022

United statesWills eye hospitalPalo altoJason ehrlichVictor perlrothCarl regilloRetina service at wills eye hospitalKodiak sciences incKodiak sciencesChief executiveRetina serviceChief medical officerChief development officerAntibody biopolymer conjugateTrial identifierTrial identifiers

Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

/PRNewswire/ Kodiak Sciences Inc. (Nasdaq: KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3.

United statesWills eye hospitalPalo altoJason ehrlichVictor perlrothCarl regilloRetina service at wills eye hospitalKodiak sciences incKodiak sciencesChief executiveRetina serviceChief medical officerChief development officerAntibody biopolymer conjugateTrial identifierTrial identifiers

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.